Back to search
FDAFDA · Food and drugs·Recall number Z-0945-2019

AF 550 x 5ML/H 6" CATH, 4.5" IN, Product code MC0050XLSK5 CP, Arrow AutoFuser Disposable Pain Control Pump

Published March 6, 2019 · Recall initiated: October 2, 2018

Summary

FDA records medical device Class II recall Z-0945-2019, published March 6, 2019 and initiated October 2, 2018. Recalling firm: Arrow International Inc; Status: Terminated; Reported quantity: 1; Lot: 74J1601025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Possible cracks on the body of the fill port connector, which may result in a leak. If the leak is identified while the user is filling the pump, there may be a delay while an alternative pump is located. If the leak goes undetected it may result in a reduced level of drug delivery to the patient and consequently a lower level of pain relief than that prescribed or expected. This may result in the need for other, additional analgesic drug administration.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Arrow International Inc
Distributor
Nationwide distribution.
Lot
74J1601025
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was AF 550 x 5ML/H 6" CATH, 4.5" IN, Product code MC0050XLSK5 CP, Arrow AutoFuser Disposable Pain Control Pump recalled?

Yes. FDA published recall Z-0945-2019 on March 6, 2019. Reported hazard: Possible cracks on the body of the fill port connector, which may result in a leak. If the leak is identified while the user is filling the pump, there may be a delay while an alternative pump is located. If the leak goes undetected it may result in a reduced level of drug delivery to the patient and consequently a lower level of pain relief than that prescribed or expected. This may result in the need for other, additional analgesic drug administration.

What should I do if I have this product?

Voluntary: Firm initiated · Letter